Get the Stockscreener App
2.65
1.12%
-0.04
After Hours:
2.59
-0.06
-2.26%
Nrx Pharmaceuticals Inc stock is traded at $2.65, with a volume of 133.77K.
It is down -1.12% in the last 24 hours and up +25.47% over the past month.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
See More
Previous Close:
$2.69
Open:
$2.7
24h Volume:
133.77K
Relative Volume:
0.61
Market Cap:
$45.82M
Revenue:
-
Net Income/Loss:
$-30.15M
P/E Ratio:
-0.6625
EPS:
-4
Net Cash Flow:
$-21.66M
1W Performance:
+1.53%
1M Performance:
+25.47%
6M Performance:
+103.05%
1Y Performance:
-27.72%
1-Day Range:
$2.55
$2.705
1-Week Range:
$2.4707
$2.7199
52-Week Range:
$1.10
$6.01
Nrx Pharmaceuticals Inc Stock (NRXP) Company Profile
Name
Nrx Pharmaceuticals Inc
Sector
Industry
Phone
484-254-6134
Address
1201 ORANGE STREET, WILMINGTON
Compare NRXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRXP
Nrx Pharmaceuticals Inc
|
2.65 | 46.51M | 0 | -30.15M | -21.66M | -4.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Nrx Pharmaceuticals Inc Stock (NRXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | BTIG Research | Buy |
Nrx Pharmaceuticals Inc Stock (NRXP) Latest News
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network - MSN
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - TipRanks
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition - financial-news.co.uk
Analysts Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Target Price at $28.50 - Defense World
Stocktwits Spotlight: NRx, CVS, ReShape Lead Weekly Jump In Health Care Stock Chatter - MSN
NRX Pharmaceuticals Announces $7.8M Debt Financing Deal - TipRanks
NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - financial-news.co.uk
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21 - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida - PR Newswire
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q1 2025 Earnings Call Transcript - Insider Monkey
NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup - TipRanks
NRx Pharmaceuticals Earnings Call Highlights Progress and Optimism - TipRanks
NRX Pharmaceuticals: A Promising Investment with Innovative Growth and Strong Financial Outlook - TipRanks
NRx Pharmaceuticals (NASDAQ:NRXP) Earns Buy Rating from D. Boral Capital - Defense World
NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE’s Strategic Kadima Agreement - TipRanks
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress on Ketamine NDA and HOPE Clinic Rollup - Yahoo Finance
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 20 - GuruFocus
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions - The Malaysian Reserve
Earnings call transcript: NRx Pharmaceuticals targets profitability by end of 2025 in Q1 2025 - Investing.com Canada
NRx Pharmaceuticals Reports Q1 2025 Results and Strategic Progress - TipRanks
Transcript : NRx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
NRX Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HOPE Therapeutics secures $7.8 million for clinic acquisitions By Investing.com - Investing.com South Africa
$7.8 Million in New Financing for Clinic Acquisitions Supporting Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression and PTSD: NRXP - FinancialContent
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Kilgore News Herald
NRX Pharmaceuticals Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Set to Report Q1 Earnings in Wake of HOPE's Strategic Kadima Agreement - Yahoo Finance
HOPE Therapeutics Subsidiary of NRx Pharmaceuticals Signs Term Sheet for $7.8M Debt Financing - citybiz
HOPE Therapeutics secures $7.8 million for clinic acquisitions - Investing.com Australia
NRX Pharmaceuticals Gets $7.8 Million Debt Financing From Universal Capital - marketscreener.com
HOPE Therapeutics and NRx Pharmaceuticals to buy Kadima Institute - MSN
NRXP Expands with Acquisition of Kadima Neuropsychiatry Institut - GuruFocus
Plan Signed to Purchase Kadima Neuropsychiatry Institute as - openPR.com
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) - Barchart.com
Plan Signed to Purchase Kadima Neuropsychiatry Institute as Clinical Treatment Model and Leading Investigative Site Addressing Suicidal Depression and PTSD: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) | FinancialContent - FinancialContent
IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute - Yahoo Finance
NRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary HOPE Therapeutics to Acquire Kadima Neuropsychiatry Institute - The Globe and Mail
NRx Pharma, Hope in pact to buy Kadima (NRXP:NASDAQ) - Seeking Alpha
HOPE Therapeutics to acquire Kadima Neuropsychiatry By Investing.com - Investing.com Nigeria
HOPE Therapeutics To Buy Kadima Neuropsychiatry Institute For Undisclosed Sum - Nasdaq
HOPE Therapeutics to acquire Kadima Neuropsychiatry - Investing.com
HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of In - StreetInsider
NRx Pharmaceuticals (NASDAQ: NRXP) to Report Q1 2025 Results on May 15 - The Globe and Mail
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 - BioSpace
Nrx Pharmaceuticals Inc Stock (NRXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):